• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

ADA 2018: CV Benefits of SGLT-2 Inhibitors

Slideshow

Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit ©Tada Images/stock.adobe.com

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

Grace Halsey
November 1st 2024
Article

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Site Logo

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Edward J. Shahady, MD
May 8th 2013
Podcast

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

September Issue of Patient Care Online Supplement is Now Live

September Issue of Patient Care Online Supplement is Now Live

Sydney Jennings
September 23rd 2024
Article

Find details on advances in the management of type 1 diabetes, utilization of CGM in primary care settings, and optimizing T2D management in older persons.

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Edward J. Shahady, MD
March 4th 2013
Podcast

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment

Sydney Jennings
September 11th 2024
Article

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

FDA Expands Omnipod 5 AID System Label to Treat T2D: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Expands Omnipod 5 AID System Label to Treat T2D: Daily Dose

Sydney Jennings
September 10th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.